Taro Pharmaceutical Industries Ltd. (TARO)
| Market Cap | 2.74B |
| Revenue (ttm) | 575.56M |
| Net Income (ttm) | -302.67M |
| Shares Out | 38.25M |
| EPS (ttm) | -7.91 |
| PE Ratio | n/a |
| Forward PE | 18.38 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $71.46 |
| Previous Close | $71.50 |
| Change ($) | -0.04 |
| Change (%) | -0.06% |
| Day's Open | 71.28 |
| Day's Range | 71.12 - 72.69 |
| Day's Volume | 9,777 |
| 52-Week Range | 53.95 - 80.00 |
Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript
Taro (TARO) delivered earnings and revenue surprises of 53.25% and 14.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Taro (TARO) delivered earnings and revenue surprises of -34.48% and -25.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.
Value investors like companies with strong balance sheets and no debt; it means there are no worries about the company going broke or getting into serious financial trouble.
Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript
Taro (TARO) delivered earnings and revenue surprises of -7.19% and 3.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical Industries Ltd (NYSE: TARO) former Vice President of Sales and Marketing Ara Aprahamian has been indicted by the Justice Department for price-fixing and bid-rigging on Tues...
Taro (TARO) delivered earnings and revenue surprises of 14.29% and -14.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript
Taro (TARO) delivered earnings and revenue surprises of -15.12% and -4.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Taro has inherited a top tier balance sheet due to management's refusal to engage in LBOs during the drug acquisition bubble of 2014-2015.
Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q4 2019 Results - Earnings Call Transcript
Taro (TARO) delivered earnings and revenue surprises of -32.74% and -5.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
About TARO
Taro Pharmaceutical Industries, a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antip... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1959 |
| CEO Uday Baldota | Employees 1,464 |
| Stock Exchange NYSE | Ticker Symbol TARO |
Financial Performance
In 2019, TARO's revenue was $644.77 million, a decrease of -3.75% compared to the previous year's $669.89 million. Earnings were $244.24 million, a decrease of -13.32%.
Analyst Forecasts
According to one analyst, the rating for TARO stock is "Buy" and the 12-month stock price forecast is 81.00.